

Appendix

Nationwide trends in glucose-lowering drug use in Denmark, 1999-2014

Diana Hedevang Christensen¹

Jørgen Rungby^{2,3}

Reimar Wernich Thomsen¹

¹*Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark*

²*Department of Pharmacology, University of Aarhus, Aarhus, Denmark*

³*Department of Endocrinology, Gentofte University Hospital, Copenhagen, Denmark*

Table S1: Annual prevalence of glucose-lowering drug users in Denmark (per 1,000 inhabitants), 1999-2014, **women.**

Table S2: Annual prevalence of insulin users in Denmark (per 1,000 inhabitants), 1999-2014, **women.**

Table S3: Annual prevalence of glucose-lowering drug users in Denmark (per 1,000 inhabitants), 1999-2014, **men.**

Table S4: Annual prevalence of insulin users in Denmark (per 1,000 inhabitants), 1999-2014, **men.**

Table S5: Annual prevalence of glucose-lowering drug users in Denmark (per 1,000 inhabitants), 1999-2014, **age-group <20 years.**

Table S6: Annual prevalence of glucose-lowering drug users in Denmark (per 1,000 inhabitants), 1999-2014, **age-group 20-39 years.**

Table S7: Annual prevalence of glucose-lowering drug users in Denmark (per 1,000 inhabitants), 1999-2014, **age-group 40-64 years.**

Table S8: Annual prevalence of glucose-lowering drug users in Denmark (per 1,000 inhabitants), 1999-2014, **age-group 65-79 years.**

Table S9: Annual prevalence of glucose-lowering drug users in Denmark (per 1,000 inhabitants), 1999-2014, **age-group ≥ 80 years.**

Table S10: Annual prevalence of insulin users in Denmark (per 1,000 inhabitants), 1999-2014, **age-group <20 years.**

Table S11: Annual prevalence of insulin users in Denmark (per 1,000 inhabitants), 1999-2014, **age-group 20-39 years.**

Table S12: Annual prevalence of insulin users in Denmark (per 1,000 inhabitants), 1999-2014, **age-group 40-64 years.**

Table S13: Annual prevalence of insulin users in Denmark (per 1,000 inhabitants), 1999-2014, **age-group 65-79 years.**

Table S14: Annual prevalence of insulin users in Denmark (per 1,000 inhabitants), 1999-2014, **age-group ≥ 80 years.**

Figure S1: Annual prevalence of all glucose-lowering drug-users (a) and insulin users (b) in Denmark per 1,000 inhabitants, 1999-2014, **women.**

Figure S2: Annual prevalence of all glucose-lowering drug-users (a) and insulin users (b) in Denmark per 1,000 inhabitants, 1999-2014, **men.**

Figure S3: Annual prevalence of all glucose-lowering drug-users (a) and insulin users (b) in Denmark per 1,000 inhabitants, 1999-2014, **age-group < 20 years.**

Figure S4: Annual prevalence of all glucose-lowering drug-users (a) and insulin users (b) in Denmark per 1,000 inhabitants, 1999-2014, **age-group 20-39 years.**

Figure S5: Annual prevalence of all glucose-lowering drug-users (a) and insulin users (b) in Denmark per 1,000 inhabitants, 1999-2014, **age-group 40-64 years.**

Figure S6: Annual prevalence of all glucose-lowering drug-users (a) and insulin users (b) in Denmark per 1,000 inhabitants, 1999-2014, **age-group 65-79 years.**

Figure S7: Annual prevalence of all glucose-lowering drug-users (a) and insulin users (b) in Denmark per 1,000 inhabitants, 1999-2014, **age-group ≥ 80 years.**

Table S1: Annual prevalence of glucose-lowering drug users in Denmark (per 1,000 inhabitants), 1999-2014, women																
	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
TOTAL	45,056 (16.76) <i>100</i>	47,377 (17.57)	49,787 (18.41)	52,418 (19.31)	56,105 (20.62)	60,430 (22.16)	64,994 (23.77)	69,297 (25.28)	73,845 (26.85)	78,448 (28.39)	82,973 (29.85)	88,410 (31.67)	94,900 (33.84)	99,929 (35.51)	101,725 (36.02)	102,467 (36.14) <i>100</i>
MET	11,313 (4.21) <i>25.1</i>	14,109 (5.23)	16,788 (6.21)	19,686 (7.25)	23,303 (8.56)	27,781 (10.19)	32,301 (11.81)	36,844 (13.44)	41,924 (15.24)	47,622 (17.23)	53,524 (19.26)	59,783 (21.42)	67,316 (24.01)	72,452 (25.75)	73,705 (26.1)	73,929 (26.08) <i>72.1</i>
INS	18,428 (6.86) <i>40.9</i>	19,462 (7.22)	20,246 (7.48)	21,351 (7.87)	22,583 (8.3)	24,027 (8.81)	25,434 (9.3)	26,627 (9.71)	27,752 (10.09)	28,607 (10.35)	29,289 (10.54)	29,851 (10.69)	30,098 (10.73)	30,676 (10.9)	31,377 (11.11)	32,140 (11.34) <i>31.4</i>
SU	25,660 (9.55) <i>57.0</i>	25,753 (9.55)	26,119 (9.66)	26,259 (9.67)	27,169 (9.98)	27,741 (10.17)	27,774 (10.16)	27,285 (9.95)	27,168 (9.88)	26,349 (9.54)	24,748 (8.9)	23,368 (8.37)	21,128 (7.53)	18,669 (6.63)	16,415 (5.81)	14,341 (5.06) <i>14.0</i>
GLP-1	-	-	-	-	-	-	-	-	68 (0.02)	529 (0.19)	1,469 (0.52)	4,462 (1.6)	6,547 (2.33)	7,874 (2.8)	8,369 (2.96)	8,574 (3.02) <i>8.4</i>
DPP-4 I	-	-	-	-	-	-	-	-	939 (0.34)	2,594 (0.94)	3,122 (1.12)	4,031 (1.44)	4,926 (1.76)	5,558 (1.98)	6,321 (2.24)	7,300 (2.57) <i>7.1</i>
MET + DPP-4 I	-	-	-	-	-	-	-	-	-	387 (0.14)	1,484 (0.54)	2,662 (0.95)	3,769 (1.34)	4,501 (1.6)	5,226 (1.85)	5,818 (2.05) <i>5.7</i>
SGLT-2 I	-	-	-	-	-	-	-	-	-	-	-	-	-	6 (0)	790 (0.28)	1,737 (0.61) <i>1.7</i>
MEGLI	929 (0.35) <i>2.06</i>	1,134 (0.42)	1,200 (0.44)	1,173 (0.43)	1,163 (0.43)	1,027 (0.38)	924 (0.34)	830 (0.3)	762 (0.28)	698 (0.25)	607 (0.22)	546 (0.2)	442 (0.16)	374 (0.13)	358 (0.13)	325 (0.11) <i>0.3</i>
A-GLU	1,049 (0.39) <i>2.3</i>	870 (0.32)	767 (0.28)	610 (0.22)	524 (0.19)	445 (0.16)	377 (0.14)	339 (0.12)	292 (0.11)	274 (0.1)	226 (0.08)	197 (0.07)	166 (0.06)	150 (0.05)	130 (0.05)	92 (0.03) <i>0.09</i>
GLITZ	-	47 (0.02)	344 (0.13)	363 (0.13)	399 (0.15)	470 (0.17)	534 (0.2)	653 (0.24)	723 (0.26)	607 (0.22)	570 (0.21)	437 (0.16)	128 (0.05)	106 (0.04)	95 (0.03)	63 (0.02) <i>0.06</i>
MET + SGLT-2 I	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	44 (0.02) <i>0.04</i>
MET + GLITZ	-	-	-	-	-	324 (0.12)	675 (0.25)	1,175 (0.43)	1,489 (0.54)	1,299 (0.47)	1,150 (0.41)	987 (0.35)	29 (0.01)	-	-	-

Notes: The percentage of patients prescribed different therapies is shown for the first year 1999 and for last year 2014 (written in italics)
The number of patients prescribed different therapies in a given year is higher than the total number of glucose-lowering drug users that year due to possibility of polypharmacy and drug-shifters
Abbreviations: MET, metformin; INS, insulin; SU, sulfonylureas; GLP-1, glucagon-like peptide 1 agonists; DPP-4 I, dipeptidylpeptidase 4 inhibitors; MET + DPP-4 I, combination formula with metformin + dipeptidylpeptidase 4 inhibitor; SGLT-2 I, sodium glucose co-transporter 2 inhibitors; MEGLI, meglitinides; A-GLU, alfa glucosidase inhibitors; GLITZ, thiazolidinediones; MET + SGLT-2 I, combination formula with metformin + sodium glucose co-transporter 2 inhibitors); MET + GLITZ, combination formula with metformin + thiazolidinediones.

Table S2: Annual prevalence of insulin users in Denmark (per 1,000 inhabitants), 1999-2014, women

	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
INS	18,428 (6.86) <i>100</i>	19,462 (7.22)	20,246 (7.48)	21,351 (7.87)	22,583 (8.3)	24,027 (8.81)	25,434 (9.3)	26,627 (9.71)	27,752 (10.09)	28,607 (10.35)	29,289 (10.54)	29,851 (10.69)	30,098 (10.73)	30,676 (10.9)	31,377 (11.11)	32,140 (11.34) <i>100</i>
LONG	2 (0) <i>0.01</i>	4 (0)	-	-	-	1,261 (0.46)	3,393 (1.24)	4,644 (1.69)	5,711 (2.08)	8,355 (3.02)	10,596 (3.81)	11,872 (4.25)	12,972 (4.63)	14,016 (4.98)	14,864 (5.26)	16,130 (5.69) <i>50.2</i>
FAST	9,177 (3.41) <i>49.8</i>	9,673 (3.59)	9,827 (3.63)	10,350 (3.81)	10,843 (3.98)	11,280 (4.14)	11,767 (4.3)	12,239 (4.46)	12,781 (4.65)	13,205 (4.78)	13,690 (4.93)	14,060 (5.04)	14,328 (5.11)	14,896 (5.29)	15,322 (5.43)	16,006 (5.65) <i>49.8</i>
INTERM	15,010 (5.58) <i>81.5</i>	15,783 (5.85)	15,906 (5.88)	16,949 (6.24)	17,528 (6.44)	17,689 (6.49)	17,004 (6.22)	16,010 (5.84)	15,353 (5.58)	14,009 (5.07)	12,154 (4.37)	11,008 (3.94)	10,015 (3.57)	9,524 (3.38)	9,326 (3.3)	8,904 (3.14) <i>27.7</i>
MIXED	5,934 (2.21) <i>32.2</i>	6,406 (2.38)	6,836 (2.53)	7,217 (2.66)	7,953 (2.92)	8,759 (3.21)	9,405 (3.44)	9,979 (3.64)	10,642 (3.87)	10,226 (3.7)	9,449 (3.4)	8,871 (3.18)	8,257 (2.94)	7,783 (2.77)	7,365 (2.61)	6,925 (2.44) <i>21.5</i>

Notes: The percentage of patients prescribed different insulin subtypes is shown for the first year 1999 and last year 2014 (written in italics). The number of patients prescribed different insulin subtypes in a given year is higher than the total number of insulin users that year due to possibility of polypharmacy and drug-shifters.

Abbreviations: INS, insulin; LONG, long-acting insulin; FAST, fast-acting insulin; INTERM, intermediate-acting insulin; MIXED, combination formula (intermediate-/long-acting insulin + fast-acting insulin).

Tables S3: Annual prevalence of glucose-lowering drug users in Denmark (per 1,000 inhabitants), 1999-2014, men																
	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
TOTAL	53,303 (20.3) <i>100</i>	56,555 (21.47)	60,030 (22.7)	63,838 (24.05)	68,713 (25.81)	73,688 (27.6)	78,359 (29.27)	83,600 (31.3)	89,271 (33.1)	95,880 (35.35)	102,650 (37.57)	110,166 (40.16)	118,930 (43.14)	125,610 (45.4)	128,410 (46.21)	130,763 (46.83) <i>100</i>
MET	11,424 (4.35) <i>21.4</i>	14,864 (5.64)	18,269 (6.91)	22,005 (8.29)	26,598 (9.99)	31,749 (11.89)	36,213 (13.53)	41,456 (15.43)	47,815 (17.73)	55,742 (20.55)	64,071 (23.45)	72,954 (26.59)	82,976 (30.1)	89,984 (32.52)	92,039 (33.12)	93,387 (33.44) <i>71.4</i>
INS	22,005 (8.38) <i>41.3</i>	23,345 (8.86)	24,223 (9.16)	25,745 (9.7)	27,477 (10.32)	29,333 (10.99)	31,072 (11.61)	32,888 (12.24)	34,864 (12.93)	36,401 (13.42)	37,975 (13.9)	39,058 (14.24)	40,102 (14.55)	41,229 (14.9)	42,533 (15.31)	43,704 (15.65) <i>33.4</i>
SU	30,060 (11.45) <i>56.4</i>	30,597 (11.62)	31,747 (12.01)	32,675 (12.31)	34,204 (12.85)	35,291 (13.22)	36,091 (13.48)	36,429 (13.56)	36,611 (13.58)	36,081 (13.3)	34,800 (12.74)	33,049 (12.05)	30,352 (11.01)	26,868 (9.71)	23,748 (8.55)	21,094 (7.55) <i>16.1</i>
GLP-1	-	-	-	-	-	-	-	-	110 (0.04)	655 (0.24)	1,999 (0.73)	6,010 (2.19)	8,732 (3.17)	10,542 (3.81)	11,287 (4.06)	11,373 (4.07) <i>8.7</i>
DPP-4 I	-	-	-	-	-	-	-	-	1,362 (0.51)	3,725 (1.37)	4,564 (1.67)	5,903 (2.15)	6,900 (2.5)	7,568 (2.74)	8,773 (3.16)	10,144 (3.63) <i>7.8</i>
MET + DPP-4 I	-	-	-	-	-	-	-	-	-	542 (0.2)	2,189 (0.8)	4,100 (1.49)	5,877 (2.13)	7,240 (2.62)	8,494 (3.06)	9,782 (3.49) <i>7.5</i>
SGLT-2 I	-	-	-	-	-	-	-	-	-	-	-	-	-	14 (0.1)	1,176 (0.42)	2,661 (0.95) <i>2.0</i>
MEGLI	1,237 (0.47) <i>2.3</i>	1,497 (0.57)	1,594 (0.6)	1,639 (0.62)	1,645 (0.62)	1,418 (0.53)	1,322 (0.49)	1,222 (0.45)	1,116 (0.41)	1,026 (0.38)	902 (0.33)	803 (0.29)	679 (0.25)	566 (0.2)	525 (0.19)	464 (0.17) <i>0.4</i>
A-GLU	1,176 (0.45) <i>2.2</i>	1,010 (0.38)	878 (0.33)	692 (0.26)	598 (0.22)	513 (0.19)	442 (0.17)	380 (0.14)	323 (0.12)	293 (0.11)	252 (0.09)	219 (0.08)	185 (0.07)	169 (0.06)	143 (0.05)	70 (0.03) <i>0.05</i>
GLITZ	-	55 (0.02)	382 (0.14)	456 (0.17)	475 (0.18)	558 (0.21)	621 (0.23)	749 (0.28)	853 (0.32)	755 (0.28)	712 (0.26)	564 (0.21)	181 (0.07)	146 (0.05)	119 (0.04)	91 (0.03) <i>0.07</i>
MET + SGLT-2 I	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	79 (0.03) <i>0.06</i>
MET + GLITZ	-	-	-	-	1 (0)	415 (0.16)	927 (0.35)	1,722 (0.64)	2,255 (0.84)	1,975 (0.73)	1,766 (0.65)	1,454 (0.53)	56 (0.02)	-	-	-

Notes: The percentage of patients prescribed different therapies is shown for the first year 1999 and for last year 2014 (written in italics)
The number of patients prescribed different therapies in a given year is higher than the total number of glucose-lowering drug users that year due to possibility of polypharmacy and drug-shifters
Abbreviations: MET, metformin; INS, insulin; SU, sulfonylureas; GLP-1, glucagon-like peptide 1 agonists; DPP-4 I, dipeptidylpeptidase 4 inhibitors; MET + DPP-4 I, combination formula with metformin + dipeptidylpeptidase 4 inhibitor; SGLT-2 I, sodium glucose co-transporter 2 inhibitors; MEGLI, meglitinides; A-GLU, alfa glucosidase inhibitors; GLITZ, thiazolidinediones; MET + SGLT-2 I, combination formula with metformin + sodium glucose co-transporter 2 inhibitors); MET + GLITZ, combination formula with metformin + thiazolidinediones.

Table S4: Annual prevalence of insulin users in Denmark (per 1,000 inhabitants), 1999-2014, men																
	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
INS	22,005 (8.38) <i>100</i>	23,345 (8.86)	24,223 (9.16)	25,745 (9.7)	27,477 (10.32)	29,333 (10.99)	31,072 (11.61)	32,888 (12.24)	34,864 (12.93)	36,401 (13.42)	37,975 (13.9)	39,058 (14.24)	40,102 (14.55)	41,229 (14.9)	42,533 (15.31)	43,704 (15.65) <i>100</i>
LONG	6 (0) <i>0.03</i>	6 (0)	-	-	-	1,340 (0.5)	3,757 (1.4)	5,252 (1.96)	6,564 (2.43)	10,125 (3.73)	13,464 (4.93)	15,777 (5.75)	17,807 (6.46)	19,623 (7.09)	20,964 (7.54)	22,889 (8.2) <i>52.4</i>
FAST	12,459 (4.75) <i>56.6</i>	12,997 (4.93)	13,279 (5.02)	14,039 (5.29)	14,555 (5.47)	15,073 (5.65)	15,686 (5.86)	16,285 (6.06)	16,985 (6.3)	17,721 (6.53)	18,459 (6.76)	19,159 (6.98)	19,665 (7.13)	20,302 (7.34)	21,001 (7.56)	21,712 (7.78) <i>49.7</i>
INTERM	18,398 (7.01) <i>83.6</i>	19,266 (7.31)	19,377 (7.33)	20,753 (7.82)	21,728 (8.16)	21,942 (8.22)	21,219 (7.93)	20,429 (7.61)	19,793 (7.34)	18,204 (6.71)	16,120 (5.9)	14,668 (5.35)	13,435 (4.87)	12,802 (4.63)	12,720 (4.58)	12,230 (4.38) <i>28.0</i>
MIXED	6,120 (2.33) <i>27.8</i>	6,688 (2.54)	7,174 (2.71)	7,782 (2.93)	8,729 (3.28)	9,916 (3.71)	10,813 (4.04)	11,827 (4.4)	12,894 (4.78)	12,895 (4.75)	12,207 (4.47)	11,546 (4.21)	10,898 (3.95)	10,296 (3.72)	9,723 (3.5)	9,106 (3.26) <i>20.8</i>
<p>Notes: The percentage of patients prescribed different insulin subtypes is shown for the first year 1999 and last year 2014 (written in italics). The number of patients prescribed different insulin subtypes in a given year is higher than the total number of insulin users that year due to possibility of polypharmacy and drug-shifters.</p> <p>Abbreviations: INS, insulin; LONG, long-acting insulin; FAST, fast-acting insulin; INTERM, intermediate-acting insulin; MIXED, combination formula (intermediate-/long-acting insulin + fast-acting insulin).</p>																

Table S5: Annual prevalence of glucose-lowering drug users in Denmark (per 1,000 inhabitants), 1999-2014, age-group < 20 years																
	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
TOTAL	2,052 (6.87) <i>100</i>	2,103 (6.99)	2,169 (7.13)	2,287 (7.39)	2,399 (7.63)	2,579 (8.05)	2,765 (8.48)	2,905 (8.76)	3,042 (9.06)	3,183 (9.37)	3,288 (9.6)	3,427 (9.94)	3,533 (10.22)	3,627 (10.46)	3,656 (10.61)	3,663 (10.68) <i>100</i>
MET	18 (0.07) <i>0.9</i>	18 (0.07)	28 (0.1)	49 (0.17)	71 (0.23)	73 (0.24)	127 (0.42)	151 (0.47)	188 (0.58)	207 (0.61)	226 (0.67)	271 (0.77)	265 (0.76)	275 (0.77)	253 (0.71)	239 (0.68) <i>6.5</i>
INS	2,029 (6.79) <i>98.9</i>	2,082 (6.93)	2,142 (7.04)	2,238 (7.22)	2,328 (7.38)	2,496 (7.78)	2,642 (8.08)	2,751 (8.28)	2,853 (8.48)	2,971 (8.74)	3,068 (8.94)	3,174 (9.21)	3,277 (9.49)	3,363 (9.73)	3,415 (9.94)	3,430 (10.02) <i>93.6</i>
SU	14 (0.05) <i>0.7</i>	12 (0.04)	12 (0.04)	20 (0.07)	22 (0.08)	25 (0.08)	18 (0.06)	19 (0.06)	26 (0.08)	29 (0.08)	25 (0.08)	19 (0.05)	24 (0.07)	25 (0.08)	18 (0.04)	10 (0.03) <i>0.3</i>
GLP-1	-	-	-	-	-	-	-	-	-	-	3 (0.01)	6 (0.02)	10 (0.03)	14 (0.04)	12 (0.03)	12 (0.04) <i>0.3</i>
DPP-4 I	-	-	-	-	-	-	-	-	2 (0.01)	-	4 (0.01)	2 (0.01)	2 (0.01)	3 (0.01)	5 (0.01)	7 (0.02) <i>0.2</i>
MET + DPP-4 I	-	-	-	-	-	-	-	-	-	-	-	-	2 (0.01)	2 (0)	-	2 (0) <i>0.05</i>
SGLT-2 I	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2 (0.01)	2 (0) <i>0.05</i>
MEGLI	2 (0.01) <i>0.1</i>	1 (0)	2 (0.01)	2 (0)	2 (0)	2 (0)	1 (0)	1 (0)	0 -	1 (0)	2 (0.01)	3 (0.01)	2 (0.01)	2 (0.01)	4 (0.01)	5 (0.02) <i>0.14</i>
A-GLU	1 (0) <i>0.05</i>	1 (0)	2 (0.01)	2 (0.01)	2 (0.01)	1 (0)	-	-	-	-	-	-	-	-	-	-
GLITZ	-	-	-	2 (0.01)	2 (0.01)	2 (0.01)	2 (0.01)	2 (0.01)	1 (0)	1 (0)	-	-	-	-	-	-
MET + SGLT-2 I	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
MET + GLITZ	-	-	-	-	-	-	-	-	1 (0)	3 (0.01)	-	-	-	-	-	-

Notes: The percentage of patients prescribed different therapies is shown for the first year 1999 and for last year 2014 (written in italics)
The number of patients prescribed different therapies in a given year is higher than the total number of glucose-lowering drug users that year due to possibility of polypharmacy and drug-shifters
Abbreviations: MET, metformin; INS, insulin; SU, sulfonylureas; GLP-1, glucagon-like peptide 1 agonists; DPP-4 I, dipeptidylpeptidase 4 inhibitors; MET + DPP-4 I, combination formula with metformin + dipeptidylpeptidase 4 inhibitor; SGLT-2 I, sodium glucose co-transporter 2 inhibitors; MEGLI, meglitinides; A-GLU, alfa glucosidase inhibitors; GLITZ, thiazolidinediones; MET + SGLT-2 I, combination formula with metformin + sodium glucose co-transporter 2 inhibitors); MET + GLITZ, combination formula with metformin + thiazolidinediones.

Table S6: Annual prevalence of glucose-lowering drug users in Denmark (per 1,000 inhabitants), 1999-2014, age-group 20-39 years																
	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
TOTAL	9,944 (6.42) <i>100</i>	10,208 (6.63)	10,307 (6.75)	10,693 (7.08)	11,236 (7.54)	12,025 (8.21)	13,199 (9.19)	14,122 (10)	14,735 (10.62)	14,962 (10.86)	15,446 (11.2)	15,921 (11.55)	16,104 (11.66)	16,291 (11.81)	16,295 (11.79)	16,076 (11.57) <i>100</i>
MET	937 (0.6) <i>9.4</i>	1,289 (0.84)	1,589 (1.04)	1,981 (1.31)	2,613 (1.75)	3,589 (2.45)	4,928 (3.43)	5,996 (4.25)	6,691 (4.82)	7,053 (5.12)	7,717 (5.6)	8,279 (6.01)	8,493 (6.15)	8,653 (6.27)	8,514 (6.16)	8,190 (5.89) <i>50.9</i>
INS	8,457 (5.46) <i>85.0</i>	8,498 (5.52)	8,384 (5.49)	8,422 (5.58)	8,453 (5.67)	8,393 (5.73)	8,335 (5.8)	8,315 (5.89)	8,310 (5.99)	8,313 (6.03)	8,287 (6.01)	8,217 (5.96)	8,149 (5.9)	8,159 (5.91)	8,231 (5.96)	8,351 (6.01) <i>51.9</i>
SU	1,163 (0.75) <i>11.7</i>	1,128 (0.73)	1,174 (0.77)	1,254 (0.83)	1,254 (0.84)	1,283 (0.88)	1,253 (0.87)	1,226 (0.87)	1,165 (0.84)	1,128 (0.82)	1,067 (0.77)	929 (0.67)	820 (0.59)	682 (0.49)	600 (0.43)	513 (0.37) <i>3.2</i>
GLP-1	-	-	-	-	-	-	-	-	18 (0.01)	105 (0.08)	240 (0.17)	623 (0.45)	846 (0.61)	971 (0.7)	957 (0.69)	895 (0.64) <i>5.6</i>
DPP-4 I	-	-	-	-	-	-	-	-	83 (0.06)	228 (0.17)	233 (0.17)	231 (0.17)	264 (0.19)	264 (0.19)	305 (0.22)	346 (0.25) <i>2.2</i>
MET + DPP-4 I	-	-	-	-	-	-	-	-	-	28 (0.02)	127 (0.09)	176 (0.13)	213 (0.15)	267 (0.19)	333 (0.24)	375 (0.26) <i>2.3</i>
SGLT-2 I	-	-	-	-	-	-	-	-	-	-	-	-	-	-	76 (0.05)	159 (0.11) <i>1.0</i>
MEGLI	78 (0.05) <i>0.8</i>	89 (0.06)	90 (0.06)	82 (0.05)	65 (0.04)	58 (0.04)	59 (0.04)	45 (0.03)	33 (0.02)	29 (0.02)	31 (0.02)	26 (0.02)	25 (0.02)	23 (0.02)	20 (0.01)	11 (0.01) <i>0.07</i>
A-GLU	61 (0.04) <i>0.6</i>	28 (0.02)	26 (0.02)	20 (0.01)	19 (0.01)	14 (0.01)	13 (0.01)	12 (0.01)	13 (0.01)	10 (0.01)	10 (0.01)	11 (0.01)	10 (0.01)	5 (0)	14 (0.01)	15 (0.01) <i>0.09</i>
GLITZ	-	3 (0)	19 (0.01)	26 (0.02)	44 (0.03)	42 (0.03)	48 (0.03)	65 (0.05)	73 (0.05)	53 (0.04)	51 (0.04)	27 (0.02)	9 (0.01)	7 (0.01)	7 (0.01)	7 (0.01) <i>0.04</i>
MET + SGLT-2 I	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5 (0) <i>0.03</i>
MET + GLITZ	-	-	-	-	-	31 (0.02)	58 (0.04)	107 (0.08)	129 (0.09)	99 (0.07)	77 (0.06)	38 (0.03)	-	-	-	-

Notes: The percentage of patients prescribed different therapies is shown for the first year 1999 and for last year 2014 (written in italics)
The number of patients prescribed different therapies in a given year is higher than the total number of glucose-lowering drug users that year due to possibility of polypharmacy and drug-shifters
Abbreviations: MET, metformin; INS, insulin; SU, sulfonylureas; GLP-1, glucagon-like peptide 1 agonists; DPP-4 I, dipeptidylpeptidase 4 inhibitors; MET + DPP-4 I, combination formula with metformin + dipeptidylpeptidase 4 inhibitor; SGLT-2 I, sodium glucose co-transporter 2 inhibitors; MEGLI, meglitinides; A-GLU, alfa glucosidase inhibitors; GLITZ, thiazolidinediones; MET + SGLT-2 I, combination formula with metformin + sodium glucose co-transporter 2 inhibitors); MET + GLITZ, combination formula with metformin + thiazolidinediones.

Table S7: Annual prevalence of glucose-lowering drug users in Denmark (per 1,000 inhabitants), 1999-2014, age-group 40-64 years																
	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
TOTAL	41,726 (24.28) 100	44,839 (25.82)	48,116 (27.38)	51,538 (29.02)	55,918 (31.16)	60,373 (33.24)	64,409 (35.01)	68,941 (37.01)	73,564 (38.97)	78,241 (41.17)	82,666 (43.38)	87,402 (45.97)	92,397 (48.79)	95,458 (50.58)	95,343 (50.58)	95,007 (50.39) 100
MET	11,776 (6.85) 28.2	15,266 (8.79)	18,741 (10.67)	22,248 (12.53)	26,541 (14.79)	31,271 (17.22)	35,330 (19.2)	39,855 (21.4)	44,933 (23.8)	51,017 (26.84)	56,760 (29.78)	62,547 (32.9)	68,520 (36.18)	71,696 (37.99)	71,267 (37.8)	70,502 (37.4) 74.2
INS	17,485 (10.17) 41.9	18,828 (10.84)	19,710 (11.22)	21,026 (11.84)	22,508 (12.54)	24,172 (13.31)	25,743 (13.99)	27,294 (14.65)	28,821 (15.27)	29,712 (15.63)	30,454 (15.98)	30,489 (16.04)	30,370 (16.04)	30,305 (16.06)	30,571 (16.22)	30,848 (16.36) 32.5
SU	22,286 (12.97) 53.4	22,527 (12.97)	23,287 (13.25)	23,948 (13.48)	25,274 (14.08)	26,138 (14.39)	26,440 (14.37)	26,398 (14.17)	26,293 (13.93)	25,296 (13.31)	23,592 (12.38)	21,846 (11.49)	19,170 (10.12)	16,351 (8.66)	14,101 (7.48)	12,465 (6.61) 13.1
GLP-1	-	-	-	-	-	-	-	-	142 (0.08)	869 (0.46)	2,467 (1.3)	6,944 (3.66)	9,767 (5.16)	11,342 (6.01)	11,701 (6.21)	11,492 (6.1) 12.1
DPP-4 I	-	-	-	-	-	-	-	-	1,360 (0.72)	3,628 (1.91)	4,172 (2.19)	5,075 (2.67)	5,562 (2.94)	5,808 (3.08)	6,219 (3.3)	6,729 (3.57) 7.1
MET + DPP-4 I	-	-	-	-	-	-	-	-	-	552 (0.19)	2,142 (1.13)	3,707 (1.95)	5,109 (2.7)	6,004 (3.18)	6,690 (3.18)	7,425 (3.94) 7.8
SGLT-2 I	-	-	-	-	-	-	-	-	-	-	-	-	-	14 (0.01)	1,214 (0.64)	2,737 (1.45) 2.9
MEGLI	1,156 (0.67) 2.8	1,426 (0.82)	1,497 (0.85)	1,464 (0.82)	1,423 (0.79)	1,199 (0.66)	1,080 (0.59)	978 (0.53)	858 (0.45)	750 (0.39)	589 (0.31)	512 (0.27)	384 (0.2)	299 (0.16)	265 (0.14)	212 (0.11) 0.2
A-GLU	918 (0.53) 2.2	742 (0.43)	658 (0.37)	511 (0.29)	442 (0.25)	365 (0.2)	305 (0.17)	266 (0.14)	212 (0.11)	210 (0.11)	174 (0.09)	147 (0.08)	115 (0.06)	107 (0.06)	91 (0.05)	67 (0.04) 0.07
GLITZ	-	69 (0.04)	430 (0.24)	504 (0.28)	521 (0.29)	609 (0.34)	633 (0.34)	743 (0.4)	846 (0.45)	722 (0.38)	630 (0.33)	472 (0.25)	162 (0.09)	136 (0.07)	108 (0.06)	82 (0.04) 0.09
MET + SGLT-2 I	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	74 (0.04) 0.08
MET + GLITZ	-	-	-	-	1 (0)	441 (0.24)	1,001 (0.54)	1,739 (0.93)	2,226 (1.18)	1,880 (0.99)	1,574 (0.83)	1,249 (0.66)	38 (0.02)	-	-	-

Abbreviations: MET, metformin; INS, insulin; SU, sulfonylurea; GLP-1, glucagon-like peptide 1 agonist; DPP-4 I, dipeptidylpeptidase 4 inhibitors; MET, DPP-4 I, combination formula (metformin + dipeptidylpeptidase 4 inhibitor); SGLT-2 I, sodium glucose co-transporter 2 inhibitors; MEGLI, meglitinides; A-GLU, alpha glucosidase inhibitors; GLITZ, thiazolidinedione; MET + SGLT-2 I, combination formula (metformin + sodium glucose co-transporter 2 inhibitors); MET + GLITZ, combination formula (metformin + thiazolidinedione).

Percentage of patients prescribed different therapies is shown for the first year 1999 and last year 2014.

Note that the number of patients prescribed different therapies in a given year is higher than the total number of glucose-lowering drug users that year due to possibility of polypharmacy and drug-shifters.

Table S8: Annual prevalence of glucose-lowering drug users in Denmark (per 1,000 inhabitants), 1999-2014, age-group 65-79 years																
	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
TOTAL	32,654 (56.13) <i>100</i>	34,303 (58.98)	35,873 (62.04)	37,834 (65.46)	40,616 (69.86)	43,691 (74.53)	46,539 (78.66)	49,706 (82.82)	53,672 (87.95)	58,834 (93.68)	64,056 (98.75)	70,559 (104.48)	79,090 (112.14)	86,259 (116.93)	90,220 (117.61)	93,094 (117.57) <i>100</i>
MET	8,128 (13.97) <i>24.9</i>	10,144 (17.44)	12,014 (20.78)	14,222 (24.61)	16,946 (29.15)	20,220 (34.49)	23,080 (39.01)	26,508 (44.17)	31,011 (50.82)	36,872 (58.71)	43,168 (66.55)	50,426 (74.67)	59,743 (84.71)	66,786 (90.53)	69,835 (91.04)	71,646 (90.48) <i>77.0</i>
INS	9,590 (16.49) <i>29.4</i>	10,287 (17.69)	10,864 (18.79)	11,743 (20.32)	12,822 (22.06)	13,969 (23.83)	15,089 (25.5)	16,166 (26.93)	17,327 (28.39)	18,440 (29.36)	19,503 (30.07)	20,841 (30.86)	21,947 (31.12)	23,431 (31.76)	24,692 (32.19)	25,892 (32.7) <i>27.8</i>
SU	22,974 (39.49) <i>70.4</i>	23,194 (39.88)	23,407 (40.48)	23,574 (40.79)	24,362 (41.91)	24,995 (42.64)	25,337 (42.83)	25,264 (42.09)	25,473 (41.74)	25,418 (40.47)	24,734 (38.13)	23,921 (35.42)	22,575 (32.01)	20,596 (27.92)	18,588 (24.23)	16,528 (20.87) <i>17.8</i>
GLP-1	-	-	-	-	-	-	-	-	17 (0.03)	206 (0.33)	734 (1.13)	2,779 (4.11)	4,457 (6.32)	5,844 (7.92)	6,675 (8.7)	7,171 (9.06) <i>7.7</i>
DPP-4 I	-	-	-	-	-	-	-	-	745 (1.22)	2,121 (3.38)	2,743 (4.23)	3,847 (5.7)	4,919 (6.97)	5,700 (7.73)	6,730 (8.77)	7,981 (10.08) <i>8.6</i>
MET + DPP-4 I	-	-	-	-	-	-	-	-	-	304 (0.48)	1,240 (1.91)	2,509 (3.72)	3,792 (5.38)	4,797 (6.5)	5,809 (7.57)	6,649 (8.39) <i>7.1</i>
SGLT-2 I	-	-	-	-	-	-	-	-	-	-	-	-	-	6 (0.01)	633 (0.83)	1397 (1.76) <i>1.5</i>
MEGLI	788 (1.35) <i>2.4</i>	938 (1.61)	999 (1.73)	1040 (1.8)	1069 (1.84)	942 (1.61)	873 (1.48)	807 (1.34)	777 (1.27)	736 (1.17)	680 (1.05)	619 (0.92)	528 (0.75)	453 (0.61)	435 (0.57)	417 (0.53) <i>0.4</i>
A-GLU	949 (1.63) <i>2.9</i>	838 (1.44)	713 (1.23)	548 (0.95)	481 (0.83)	409 (0.7)	356 (0.6)	307 (0.51)	270 (0.44)	233 (0.37)	202 (0.31)	184 (0.27)	168 (0.24)	157 (0.21)	128 (0.17)	52 (0.07) <i>0.06</i>
GLITZ	-	27 (0.05)	239 (0.41)	249 (0.43)	256 (0.44)	320 (0.55)	407 (0.69)	487 (0.81)	524 (0.86)	479 (0.76)	499 (0.77)	419 (0.62)	115 (0.16)	90 (0.12)	83 (0.11)	52 (0.07) <i>0.06</i>
MET + SGLT-2 I	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	41 (0.05) <i>0.04</i>
MET + GLITZ	-	-	-	-	-	234 (0.4)	478 (0.81)	939 (1.56)	1,215 (1.99)	1,138 (1.81)	1,099 (1.69)	1,006 (1.49)	38 (0.05)	-	-	-

Notes: The percentage of patients prescribed different therapies is shown for the first year 1999 and for last year 2014 (written in italics)
The number of patients prescribed different therapies in a given year is higher than the total number of glucose-lowering drug users that year due to possibility of polypharmacy and drug-shifters
Abbreviations: MET, metformin; INS, insulin; SU, sulfonylureas; GLP-1, glucagon-like peptide 1 agonists; DPP-4 I, dipeptidylpeptidase 4 inhibitors; MET + DPP-4 I, combination formula with metformin + dipeptidylpeptidase 4 inhibitor; SGLT-2 I, sodium glucose co-transporter 2 inhibitors; MEGLI, meglitinides; A-GLU, alfa glucosidase inhibitors; GLITZ, thiazolidinediones; MET + SGLT-2 I, combination formula with metformin + sodium glucose co-transporter 2 inhibitors); MET + GLITZ, combination formula with metformin + thiazolidinediones.

Table S9: Annual prevalence of glucose-lowering drug users in Denmark (per 1,000 inhabitants), 1999-2014, age-group ≥ 80 years																
	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
TOTAL	11,986 (57.42) <i>100</i>	12,480 (59.76)	13,352 (62.52)	13,904 (64.2)	14,649 (67.51)	15,450 (70.75)	16,442 (74.44)	17,223 (77.29)	18,103 (80.63)	19,108 (84.91)	20,167 (88.9)	21,267 (93.48)	22,706 (99.37)	23,904 (103.77)	24,621 (105.81)	25,390 (108.09) <i>100</i>
MET	1,879 (9) <i>15.7</i>	2,256 (10.8)	2,685 (12.57)	3,191 (14.73)	3,730 (17.19)	4,377 (20.04)	5,049 (22.86)	5,790 (25.98)	6,916 (30.8)	8,215 (36.5)	9,724 (42.86)	11,214 (49.29)	13,271 (58.08)	15,026 (65.23)	15,875 (68.23)	16,739 (71.26) <i>65.9</i>
INS	2,873 (13.76) <i>24.0</i>	3,113 (14.91)	3,369 (15.77)	3,667 (16.93)	3,949 (18.2)	4,330 (19.83)	4,697 (21.27)	4,989 (22.39)	5,305 (23.63)	5,572 (24.76)	5,952 (26.24)	6,188 (27.2)	6,457 (28.26)	6,647 (28.85)	7,001 (30.09)	7,323 (31.18) <i>28.8</i>
SU	9,284 (44.47) <i>77.5</i>	9,489 (45.44)	9,986 (46.76)	10,138 (46.81)	10,461 (48.21)	10,591 (48.5)	10,818 (48.98)	10,807 (48.5)	10,822 (48.2)	10,559 (46.92)	10,130 (44.65)	9,702 (42.64)	8,891 (38.91)	7,883 (34.22)	6,856 (29.46)	5,919 (25.2) <i>23.3</i>
GLP-1	-	-	-	-	-	-	-	-	1 (0)	4 (0.02)	24 (0.1)	120 (0.53)	199 (0.87)	245 (1.07)	311 (1.32)	377 (1.61) <i>1.5</i>
DPP-4 I	-	-	-	-	-	-	-	-	111 (0.49)	342 (1.52)	534 (2.35)	779 (3.42)	1,079 (4.72)	1,351 (5.86)	1,835 (7.89)	2,381 (10.14) <i>9.4</i>
MET + DPP-4 I	-	-	-	-	-	-	-	-	-	45 (0.2)	164 (0.72)	370 (1.63)	530 (2.32)	668 (2.9)	843 (3.61)	977 (4.12) <i>3.8</i>
SGLT-2 I	-	-	-	-	-	-	-	-	-	-	-	-	-	-	41 (0.18)	103 (0.43) <i>0.4</i>
MEGLI	142 (0.68) <i>1.2</i>	177 (0.85)	206 (0.96)	224 (1.03)	249 (1.15)	244 (1.12)	233 (1.05)	221 (0.99)	210 (0.94)	208 (0.92)	207 (0.91)	189 (0.83)	182 (0.8)	163 (0.71)	159 (0.68)	144 (0.61) <i>0.6</i>
A-GLU	296 (1.42) <i>2.5</i>	271 (1.3)	246 (1.15)	221 (1.02)	178 (0.82)	169 (0.77)	145 (0.66)	134 (0.6)	120 (0.53)	114 (0.51)	92 (0.41)	74 (0.33)	58 (0.25)	50 (0.22)	40 (0.17)	28 (0.12) <i>0.1</i>
GLITZ	-	3 (0.01)	38 (0.18)	38 (0.18)	51 (0.24)	55 (0.25)	65 (0.29)	105 (0.47)	132 (0.59)	107 (0.48)	102 (0.45)	83 (0.36)	23 (0.1)	19 (0.08)	16 (0.07)	13 (0.06) <i>0.05</i>
MET + SGLT-2 I	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3 (0.01) <i>0.01</i>
MET + GLITZ	-	-	-	-	-	33 (0.15)	65 (0.29)	112 (0.5)	173 (0.77)	154 (0.68)	166 (0.73)	148 (0.65)	9 (0.04)	-	-	-

Notes: The percentage of patients prescribed different therapies is shown for the first year 1999 and for last year 2014 (written in italics)
The number of patients prescribed different therapies in a given year is higher than the total number of glucose-lowering drug users that year due to possibility of polypharmacy and drug-shifters
Abbreviations: MET, metformin; INS, insulin; SU, sulfonylureas; GLP-1, glucagon-like peptide 1 agonists; DPP-4 I, dipeptidylpeptidase 4 inhibitors; MET + DPP-4 I, combination formula with metformin + dipeptidylpeptidase 4 inhibitor; SGLT-2 I, sodium glucose co-transporter 2 inhibitors; MEGLI, meglitinides; A-GLU, alfa glucosidase inhibitors; GLITZ, thiazolidinediones; MET + SGLT-2 I, combination formula with metformin + sodium glucose co-transporter 2 inhibitors); MET + GLITZ, combination formula with metformin + thiazolidinediones.

Table S10: Annual prevalence of insulin users in Denmark (per 1,000 inhabitants), 1999-2014, age-group < 20 years																
	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
INS	2,029 (6.79) <i>100</i>	2,082 (6.93)	2,142 (7.04)	2,238 (7.22)	2,328 (7.38)	2,496 (7.78)	2,642 (8.08)	2,751 (8.28)	2,853 (8.48)	2,971 (8.74)	3,068 (8.94)	3,174 (9.21)	3,277 (9.49)	3,363 (9.73)	3,415 (9.94)	3,430 (10.02) <i>100</i>
LONG	1 (0) <i>0.05</i>	2 (0)	-	-	-	200 (0.64)	593 (1.85)	1,035 (3.14)	1,364 (4.07)	1,823 (5.37)	1,906 (5.56)	1,863 (5.39)	1,805 (5.19)	1,721 (4.95)	1,617 (4.67)	1,627 (4.71) <i>47.4</i>
FAST	1,646 (5.55) <i>81.1</i>	1,785 (5.98)	1,862 (6.15)	1,964 (6.35)	2,101 (6.68)	2,279 (7.1)	2,447 (7.5)	2,563 (7.72)	2,713 (8.06)	2,861 (8.41)	2,977 (8.69)	3,105 (9.02)	3,219 (9.32)	3,303 (9.57)	3,363 (9.79)	3,374 (9.86) <i>98.4</i>
INTERM	1,137 (3.89) <i>56.0</i>	1,109 (3.81)	1,078 (3.7)	1,132 (3.8)	1,195 (3.94)	1,229 (3.94)	1,218 (3.8)	1,134 (3.42)	1,046 (3.11)	922 (2.71)	720 (2.1)	646 (1.88)	609 (1.77)	609 (1.77)	560 (1.65)	492 (1.44) <i>14.3</i>
MIXED	1,329 (4.37) <i>65.5</i>	1,456 (4.73)	1,570 (5.01)	1,690 (5.32)	1,804 (5.58)	1,942 (5.93)	1,949 (5.85)	1,812 (5.38)	1,566 (4.63)	900 (2.64)	299 (0.88)	183 (0.52)	117 (0.33)	90 (0.25)	64 (0.18)	51 (0.15) <i>1.5</i>
<p>Notes: The percentage of patients prescribed different insulin subtypes is shown for the first year 1999 and last year 2014 (written in italics). The number of patients prescribed different insulin subtypes in a given year is higher than the total number of insulin users that year due to possibility of polypharmacy and drug-shifters.</p> <p>Abbreviations: INS, insulin; LONG, long-acting insulin; FAST, fast-acting insulin; INTERM, intermediate-acting insulin; MIXED, combination formula (intermediate-/long-acting insulin + fast-acting insulin).</p>																

Table S11: Annual prevalence of insulin users in Denmark (per 1,000 inhabitants), 1999-2014, age-group 20-39 years

	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
INS	8,457 (5.46) <i>100</i>	8,498 (5.52)	8,384 (5.49)	8,422 (5.58)	8,453 (5.67)	8,393 (5.73)	8,335 (5.8)	8,315 (5.89)	8,310 (5.99)	8,313 (6.03)	8,287 (6.01)	8,217 (5.96)	8,149 (5.9)	8,159 (5.91)	8,231 (5.96)	8,351 (6.01) <i>100</i>
LONG	3 (0) <i>0.04</i>	2 (0)	- -	- -	- -	706 (0.48)	1,914 (1.33)	2,540 (1.8)	3,054 (2.2)	3,952 (2.87)	4,552 (3.3)	4,923 (3.57)	5,149 (3.73)	5,285 (3.83)	5,430 (3.93)	5,607 (4.03) <i>67.1</i>
FAST	7,395 (4.77) <i>87.4</i>	7,476 (4.85)	7,284 (4.77)	7,406 (4.9)	7,361 (4.94)	7,328 (5.01)	7,250 (5.05)	7,241 (5.13)	7,189 (5.18)	7,203 (5.23)	7,105 (5.15)	7,126 (5.17)	7,071 (5.12)	7,075 (5.13)	7,138 (5.17)	7,278 (5.24) <i>87.2</i>
INTERM	7,709 (4.98) <i>91.1</i>	7,692 (4.99)	7,230 (4.74)	7,463 (4.94)	7,363 (4.94)	6,929 (4.73)	6,145 (4.28)	5,381 (3.81)	4,808 (3.46)	3,982 (2.89)	3,178 (2.3)	2,574 (1.87)	2,113 (1.53)	1,817 (1.32)	1,660 (1.2)	1,412 (1.02) <i>16.9</i>
MIXED	1,090 (0.7) <i>12.9</i>	1,074 (0.7)	1,075 (0.7)	1,069 (0.71)	1,117 (0.75)	1,084 (0.74)	1,040 (0.72)	1,035 (0.73)	1,048 (0.76)	1,002 (0.73)	936 (0.68)	780 (0.57)	690 (0.5)	618 (0.45)	609 (0.44)	568 (0.41) <i>6.8</i>

Notes: The percentage of patients prescribed different insulin subtypes is shown for the first year 1999 and last year 2014 (written in italics). The number of patients prescribed different insulin subtypes in a given year is higher than the total number of insulin users that year due to possibility of polypharmacy and drug-shifters.

Abbreviations: INS, insulin; LONG, long-acting insulin; FAST, fast-acting insulin; INTERM, intermediate-acting insulin; MIXED, combination formula (intermediate-/long-acting insulin + fast-acting insulin).

Table S12: Annual prevalence of insulin users in Denmark (per 1,000 inhabitants), 1999-2014, age-group 40-64 years

	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
INS	17,485 (10.17) <i>100</i>	18,828 (10.84)	19,710 (11.22)	21,026 (11.84)	22,508 (12.54)	24,172 (13.31)	25,743 (13.99)	27,294 (14.65)	28,821 (15.27)	29,712 (15.63)	30,454 (15.98)	30,489 (16.04)	30,370 (16.04)	30,305 (16.06)	30,571 (16.22)	30,848 (16.36) <i>100</i>
LONG	3 (0) <i>0.02</i>	5 (0)	- -	- -	- -	1,325 (0.73)	3,612 (1.96)	4,889 (2.62)	6,017 (3.19)	8,981 (4.73)	11,784 (6.18)	13,363 (7.03)	14,682 (7.75)	15,736 (8.34)	16,433 (8.72)	17,557 (9.31) <i>56.9</i>
FAST	10,096 (5.88) <i>57.7</i>	10,693 (6.16)	11,030 (6.28)	11,745 (6.61)	12,301 (6.85)	12,722 (7)	13,311 (7.23)	13,971 (7.5)	14,654 (7.76)	15,129 (7.96)	15,628 (8.2)	15,907 (8.37)	15,983 (8.44)	16,197 (8.58)	16,478 (8.74)	16,715 (8.87) <i>54.2</i>
INTERM	15,026 (8.74) <i>85.9</i>	16,118 (9.28)	16,380 (9.32)	17,651 (9.94)	18,393 (10.25)	18,608 (10.24)	17,904 (9.73)	17,003 (9.13)	16,349 (8.66)	14,692 (7.73)	12,588 (6.61)	11,075 (5.82)	9,780 (5.16)	8,985 (4.76)	8,692 (4.61)	8,159 (4.33) <i>26.4</i>
MIXED	4,328 (2.52) <i>24.8</i>	4,727 (2.72)	5,020 (2.86)	5,457 (3.07)	6,162 (3.43)	7,169 (3.95)	7,831 (4.26)	8,678 (4.66)	9,634 (5.1)	9,614 (5.06)	9,043 (4.74)	8,233 (4.33)	7,362 (3.89)	6,598 (3.5)	5,961 (3.16)	5,410 (2.87) <i>17.5</i>

Notes: The percentage of patients prescribed different insulin subtypes is shown for the first year 1999 and last year 2014 (written in italics). The number of patients prescribed different insulin subtypes in a given year is higher than the total number of insulin users that year due to possibility of polypharmacy and drug-shifters.

Abbreviations: INS, insulin; LONG, long-acting insulin; FAST, fast-acting insulin; INTERM, intermediate-acting insulin; MIXED, combination formula (intermediate-/long-acting insulin + fast-acting insulin).

Table S13: Annual prevalence of insulin users in Denmark (per 1,000 inhabitants), 1999-2014, age-group 65-79 years


	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
INS	9,590 (16.49) <i>100</i>	10,287 (17.69)	10,864 (18.79)	11,743 (20.32)	12,822 (22.06)	13,969 (23.83)	15,089 (25.5)	16,166 (26.93)	17,327 (28.39)	18,440 (29.36)	19,503 (30.07)	20,841 (30.86)	21,947 (31.12)	23,431 (31.76)	24,692 (32.19)	25,892 (32.7) <i>100</i>
LONG	1 (0) <i>0.01</i>	-	-	-	-	340 (0.58)	922 (1.56)	1,265 (2.11)	1,635 (2.68)	3,161 (5.03)	4,817 (7.43)	6,214 (9.2)	7,514 (10.65)	8,959 (12.14)	10,120 (13.19)	11,667 (14.73) <i>45.1</i>
FAST	2,204 (3.79) <i>23.0</i>	2,367 (4.07)	2,534 (4.38)	2,854 (4.94)	3,158 (5.43)	3,462 (5.91)	3,794 (6.41)	4,043 (6.74)	4,460 (7.31)	4,882 (7.77)	5,416 (8.35)	5,991 (8.87)	6,467 (9.17)	7,187 (9.74)	7,737 (10.09)	8,545 (10.79) <i>33.0</i>
INTERM	7,402 (12.72) <i>77.2</i>	7,878 (13.55)	8,149 (14.09)	8,843 (15.3)	9,522 (16.38)	9,888 (16.87)	9,919 (16.7)	9,873 (16.45)	9,858 (16.15)	9,592 (15.27)	8,835 (13.62)	8,540 (12.65)	8,224 (11.66)	8,231 (11.16)	8,424 (10.98)	8,335 (10.53) <i>32.2</i>
MIXED	4,110 (7.07) <i>42.9</i>	4,475 (7.69)	4,826 (8.35)	5,106 (8.83)	5,736 (9.87)	6,395 (10.91)	7,066 (11.94)	7,713 (12.85)	8,463 (13.87)	8,739 (13.92)	8,568 (13.21)	8,427 (12.48)	8,290 (11.75)	8,166 (11.07)	7,884 (10.28)	7,491 (9.46) <i>28.9</i>

Notes: The percentage of patients prescribed different insulin subtypes is shown for the first year 1999 and last year 2014 (written in italics). The number of patients prescribed different insulin subtypes in a given year is higher than the total number of insulin users that year due to possibility of polypharmacy and drug-shifters.

Abbreviations: INS, insulin; LONG, long-acting insulin; FAST, fast-acting insulin; INTERM, intermediate-acting insulin; MIXED, combination formula (intermediate-/long-acting insulin + fast-acting insulin).

Table S14: Annual prevalence of insulin users in Denmark (per 1,000 inhabitants), 1999-2014, age-group ≥ 80 years																
	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
INS	2,873 (13.76) <i>100</i>	3,113 (14.91)	3,369 (15.77)	3,667 16.93	3,949 (18.2)	4,330 (19.83)	4,697 (21.27)	4,989 (22.39)	5,305 (23.63)	5,572 (24.76)	5,952 (26.24)	6,188 (27.2)	6,457 (28.26)	6,647 (28.85)	7,001 (30.09)	7,323 (31.18) <i>100</i>
LONG	-	1 0	-	-	-	30 (0.14)	109 (0.49)	167 (0.75)	205 (0.91)	563 (2.5)	1,001 (4.41)	1,286 (5.65)	1,629 (7.13)	1,938 (8.41)	2,228 (9.58)	2,561 (10.9) <i>35.0</i>
FAST	295 (1.41) <i>10.3</i>	349 (1.67)	396 (1.85)	420 (1.94)	477 (2.2)	562 (2.57)	651 (2.95)	706 (3.17)	750 (3.34)	851 (3.78)	1,023 (4.51)	1,090 (4.79)	1,253 (5.48)	1,436 (6.23)	1,607 (6.91)	1,806 (7.69) <i>24.7</i>
INTERM	2,135 (10.23) <i>74.3</i>	2,253 (10.79)	2,446 (11.45)	2,613 (12.06)	2,783 (12.83)	2,977 (13.63)	3,037 (13.75)	3,048 (13.68)	3,085 (13.74)	3,025 (13.44)	2,953 (13.02)	2,841 (12.49)	2,724 (11.92)	2,684 (11.65)	2,710 (11.65)	2,736 (11.65) <i>37.4</i>
MIXED	1,197 (5.73) <i>41.7</i>	1,362 (6.52)	1,519 (7.11)	1,677 (7.74)	1,863 (8.59)	2,085 (9.55)	2,332 (10.56)	2,568 (11.52)	2,825 (12.58)	2,866 (12.74)	2,810 (12.39)	2,794 (12.28)	2,696 (11.8)	2,607 (11.32)	2,570 (11.05)	2,511 (10.69) <i>34.3</i>
<p>Notes: The percentage of patients prescribed different insulin subtypes is shown for the first year 1999 and last year 2014 (written in italics). The number of patients prescribed different insulin subtypes in a given year is higher than the total number of insulin users that year due to possibility of polypharmacy and drug-shifters.</p> <p>Abbreviations: INS, insulin; LONG, long-acting insulin; FAST, fast-acting insulin; INTERM, intermediate-acting insulin; MIXED, combination formula (intermediate-/long-acting insulin + fast-acting insulin).</p>																


Figur S1: Annual prevalence of all glucose-lowering drug-users (a) and insulin users (b) in Denmark per 1,000 inhabitants, 1999-2014, women.



Notes: The number of persons prescribed different therapies in a given year is higher than the total number of glucose-lowering drug users that year due to possibility of polypharmacy and drug-shifters.

Abbreviations: GLP-1, glucagon-like receptor 1; DPP-4, dipeptidylpeptidase 4; SGLT-2, sodium-glucose co-transporter 2.


Figur S2: Annual prevalence of all glucose-lowering drug-users (a) and insulin users (b) in Denmark per 1,000 inhabitants, 1999-2014, men.



Notes: The number of persons prescribed different therapies in a given year is higher than the total number of glucose-lowering drug users that year due to possibility of polypharmacy and drug-shifters.

Abbreviations: GLP-1, glucagon-like receptor 1; DPP-4, dipeptidylpeptidase 4; SGLT-2, sodium-glucose co-transporter 2.


Figur S3: Annual prevalence of all glucose-lowering drug-users (a) and insulin users (b) in Denmark per 1,000 inhabitants, 1999-2014, age < 20 years.



Notes: The number of persons prescribed different therapies in a given year is higher than the total number of glucose-lowering drug users that year due to possibility of polypharmacy and drug-shifters.

Abbreviations: GLP-1, glucagon-like receptor 1; DPP-4, dipeptidylpeptidase 4; SGLT-2, sodium-glucose co-transporter 2.


Figur S4: Annual prevalence of all glucose-lowering drug-users (a) and insulin users (b) in Denmark per 1,000 inhabitants, 1999-2014, age = 20-39 years.



Notes: The number of persons prescribed different therapies in a given year is higher than the total number of glucose-lowering drug users that year due to possibility of polypharmacy and drug-shifters.

Abbreviations: GLP-1, glucagon-like receptor 1; DPP-4, dipeptidylpeptidase 4; SGLT-2, sodium-glucose co-transporter 2.


Figur S5: Annual prevalence of all glucose-lowering drug-users (a) and insulin users (b) in Denmark per 1,000 inhabitants, 1999-2014, age = 40-64 years.



Notes: The number of persons prescribed different therapies in a given year is higher than the total number of glucose-lowering drug users that year due to possibility of polypharmacy and drug-shifters.

Abbreviations: GLP-1, glucagon-like receptor 1; DPP-4, dipeptidylpeptidase 4; SGLT-2, sodium-glucose co-transporter 2.


Figur S6: Annual prevalence of all glucose-lowering drug-users (a) and insulin users (b) in Denmark per 1,000 inhabitants, 1999-2014, age = 65-79 years.



Notes: The number of persons prescribed different therapies in a given year is higher than the total number of glucose-lowering drug users that year due to possibility of polypharmacy and drug-shifters.

Abbreviations: GLP-1, glucagon-like receptor 1; DPP-4, dipeptidylpeptidase 4; SGLT-2, sodium-glucose co-transporter 2.

Figur S7: Annual prevalence of all glucose-lowering drug-users (a) and insulin users (b) in Denmark per 1,000 inhabitants, 1999-2014, age = ≥ 80 years.



The number of persons prescribed different therapies in a given year is higher than the total number of glucose-lowering drug users that year due to possibility of polypharmacy and drug-shifters.

Abbreviations: GLP-1, glucagon-like receptor 1; DPP-4, dipeptidylpeptidase 4; SGLT-2, sodium-glucose co-transporter 2.